Osteogenesis Imperfecta was the first disease for which a stem cell-based type of intervention was envisioned [43], and in which targeting

the genetic defect in stem cells ex vivo was attempted [44] and [45]. The gene defect causing FD is a dominant, gain-of-function point mutation in a ubiquitously expressed, indispensable gene. Gene correction in FD thus requires silencing of the mutated allele with absolute specificity, which per se is a greater challenge in gene therapy than gene replacement. Nonetheless, the FD-causing mutation can be efficiently and specifically corrected in human stromal progenitor ex vivo using lentivirally expressed shRNAs, resulting in reversion of the fundamental cellular phenotype represented SCH772984 datasheet by excess production of cAMP [46]. Of note, as specific genetic defects can be corrected ex vivo in skeletal stem cells, several systemic, often lethal, skeletal diseases such as Osteogenesis Imperfecta and FD could be cured as of today, if systemic infusion

of skeletal stem cells was at all feasible in the simplistic way in which it was first envisioned. Unfortunately, we are not there yet. Nonetheless, the use of stem cells, including gene-corrected BMS-907351 concentration stem cells for treating systemic diseases of the skeleton remains unfeasible until ways to deliver stem cells systemically to the skeleton becomes feasible. Conversely, stable transduction of normal stromal progenitors with disease genes using last generation lentiviral vectors provides

an additional tool for investigating the functional effects of a disease gene. In the case of FD, this exercise revealed, for example, the induction of RANKL as a robust and specific effect of the GNAS mutation, directly relevant to the origin of excess osteoclastogenesis and remodeling in FD [46], very and made it possible to investigate the transcriptome of newly mutated cells with appropriate controls and statistical robustness, circumventing the unpredictable variability of primary cultures derived from clinical material (manuscript in preparation). Hematopoietic and non-hematopoietic cancer (primary and secondary) is a major determinant of skeletal morbidity, and for this reason, cancer in bone is the source of major clinical, social and healthcare concerns. Until very recently, myeloma and metastatic growth of primary epithelial cancers were the specific focus of interest, reflecting both the occurrence of gross bone lesions as a result of their growth, and of the ease with which such lesions could be traced to an unbalance in remodeling. In this context, interest in the interaction of cancer cells with bone essentially excluded consideration of a potential role for skeletal stem cells as partners or players of the cancer–bone interaction, and in most cases even consideration of a role for bone marrow stromal cells at large.